世茂集團(00813.HK)擬發行10.48億美元優先票據
格隆匯9月14日丨世茂集團(00813.HK)發佈公吿,2021年9月13日,公司與匯豐、J.P. Morgan、摩根士丹利、交銀國際、中金公司、富強證券有限公司、SMBC Nikko、渣打銀行及大華銀行就發行3億美元於2023年到期的3.975%優先票據及7.48億美元於2027年到期的5.20%優先票據訂立購買協議。
公司擬將票據發行所得款項淨額用於為一年內到期的現有境外中長期債券再融資。在上述用途的基礎上,公司計劃根據集團的綠色金融框架,將與提呈發售2027年票據所得款項淨額等額的款項全部或部分用於為若干合資格綠色項目融資或再融資。公司已就票據於新加坡交易所上市及報價獲得新加坡交易所原則上批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.